Considering its vital role in MES gliomas and the devastating consequences of resistance to multiple therapies, finding new strategies to deactivate the NF-κB system is essential to improving clinical outcomes for glioma patients37. This evidence concerns the gene NFKB1 and central nervous system cancer.